profit from every $100 of sales.
$0$100
Mesa Laboratories
$139.21+1.68% today
+73.9% in 1 year
1-year low $70.601-year high $142.23
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Mesa Laboratories sold, what it kept, and what it did with the cash.
Sales went from $184 million in 2022 to $241 million in 2025, with -$1.97 million of profit last year.
SalesProfit
Mesa Laboratories handed back 8% of the cash it generated last year.
$3M
Free cash flow 2025$42M
Bought back its own shares–
Paid as dividends$3M
Cash vs. debt$27M vs. $181M
Mesa Laboratories vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mesa Laboratories | No profit yet | ||
 TE Connectivity | 19.3× · Fair price | ||
 Celestica | 36.8× · Expensive | ||
 Teledyne Technologies | 33.7× · Expensive | ||
 Flex | 33.2× · Expensive |
AI analysis
An AI analyst reads Mesa Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 184 | 219 | 216 | 241 | |
| 109 | 134 | 133 | 151 | |
| 5 | 3 | 2 | 16 | |
| 33 | 38 | -238 | 42 | |
| 2 | 1 | -254 | -2 | |
| 0.35 | 0.17 | -47.20 | -0.36 | |
| 59.2% | 61.0% | 61.6% | 62.6% | |
| 2.6% | 1.5% | 1.1% | 6.8% | |
| 1.0% | 0.4% | -117.6% | -0.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 707 | 662 | 447 | 433 |
| Cash | 49 | 33 | 28 | 27 |
| Total debt | 221 | 186 | 225 | 181 |
| Total liabilities | 314 | 268 | 301 | 274 |
| 394 | 393 | 145 | 160 | |
| 5 | 5 | 5 | 5 | |
| 1.0% | 0.6% | -57.6% | 4.1% | |
| 0.5% | 0.2% | -174.9% | -1.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 39 | 28 | 44 | 47 | |
| 4 | 5 | 3 | 4 | |
| 35 | 23 | 42 | 42 | |
| Dividends paid | 3 | 3 | 3 | 3 |
| – | – | – | – | |
| 11 | 13 | 12 | 13 |
Valuation
- –
- 16.3×
- –
- 3.0×
- 3.2×
- 18.5×
- 22.1×
- 5.4%
- -0.3%
- 0.6%
Profitability
- 62.6%
- 6.8%
- -0.8%
- 17.9%
- 1.2%
- -13.4%
- 2.1%
- 0.9%
- 4.5%
- 8.1%
Growth
- +9.3%
- –
- +1.8%
- +0.0%
- +2.2%
Financial health
- 1.7×
- 0.55
- 23.8%
- 1.6×
- 1.94
- 1.45
- 0.57
How it ranks in Technology
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 974
Bottom 45%of 975
Top 49%of 982
Top 21%of 985
What analysts expect
- Average price target
- $94.00
- Range
- $94.00 – $94.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 3, 2026 | 3.07 | 1.40 | +119.3% |
| Nov 6, 2025 | 1.76 | 1.56 | +12.8% |
| Aug 5, 2025 | 2.32 | 2.46 | −5.7% |
| May 28, 2025 | 2.23 | 2.75 | −18.9% |
| Feb 4, 2025 | 2.67 | 1.41 | +89.4% |
| Nov 7, 2024 | 2.45 | 2.48 | −1.2% |
| Aug 5, 2024 | 2.83 | 2.33 | +21.5% |
| Jun 5, 2024 | 2.77 | -0.11 | +2,618.2% |
0.6%of the share price, paid each year
On $1,000 invested$6a year at today's yield, before tax
+0.0%2020 to 2025
Raised–not every year
Paid per share, each year
$0.64 in 2015 → $0.64 in 2025
How safe it looks
94.0% of its profit
Room to growStretchedMore than it earns: 8.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
30No pass
Philip Fisher
40No pass
Peter Lynch
46No pass
Joel Greenblatt
2No pass
Charlie Munger
31No pass
Terry Smith
35No pass
Questions about Mesa Laboratories
Is Mesa Laboratories a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mesa Laboratories AI analysis
What does Mesa Laboratories do?
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. It is in Hardware, Equipment & Parts.
Does Mesa Laboratories pay a dividend?
Yes. At today's price the dividend is 0.6% a year, about 94% of its yearly profit. In 2025 it paid out $3.47 million in dividends.
Is Mesa Laboratories stock halal?
Yes. Mesa Laboratories passes our halal screen: its business is permitted and its debt is 23% of its market value, under the 30% limit. How we check
How has Mesa Laboratories stock done over the past year?
Up 73.9% over the past twelve months, to $139.21. It traded between $70.60 and $142.23 and is 2.1% below its high.
Who are Mesa Laboratories's competitors?
The largest listed companies in the same industry are TE Connectivity, Celestica, Teledyne Technologies and Flex. The peers table on this page compares their profit, growth and price with Mesa Laboratories's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.